{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:22:34Z","timestamp":1790716954184,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-08127-6","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:27:29Z","timestamp":1776281249000},"page":"3695-3704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pitavastatin use and reduced risk of gout: a nationwide propensity score\u2013matched cohort study"],"prefix":"10.1007","volume":"45","author":[{"given":"Chih-Hau","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Teng","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Tung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Ching","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-0305","authenticated-orcid":false,"given":"Chen-Chih","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"7081","key":"8127_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237\u2013241","journal-title":"Nature"},{"issue":"8","key":"8127_CR2","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","volume":"6","author":"M Cross","year":"2024","unstructured":"Cross M, Ong KL, Culbreth GT, Steinmetz JD, Cousin E, Lenox H et al (2024) Global, regional, and national burden of gout, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 6(8):e507\u2013e517","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"8127_CR3","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/rheumatology\/kez476","volume":"59","author":"Y Xia","year":"2020","unstructured":"Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T et al (2020) Global, regional and national burden of gout, 1990\u20132017: a systematic analysis of the Global Burden of Disease Study. Rheumatology 59(7):1529\u20131538","journal-title":"Rheumatology"},{"issue":"4","key":"8127_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"C-F Kuo","year":"2015","unstructured":"Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M (2015) Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 74(4):661\u2013667","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8127_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/rheumatology\/37.3.258","volume":"37","author":"C Chou","year":"1998","unstructured":"Chou C, Lai J (1998) The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol 37(3):258\u2013262","journal-title":"Br J Rheumatol"},{"issue":"1","key":"8127_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jbspin.2014.07.002","volume":"82","author":"F-Y Tu","year":"2015","unstructured":"Tu F-Y, Lin G-T, Lee S-S, Tung Y-C, Tu H-P, Chiang H-C (2015) Prevalence of gout with comorbidity aggregations in southern Taiwan. Joint Bone Spine 82(1):45\u201351","journal-title":"Joint Bone Spine"},{"issue":"1","key":"8127_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0522-8","volume":"17","author":"C-F Kuo","year":"2015","unstructured":"Kuo C-F, Grainge MJ, See L-C, Yu K-H, Luo S-F, Zhang W et al (2015) Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther 17(1):13","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"8127_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello\u2010Petersen R, Guyatt G, Abeles AM et al (2020) 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol 72(6):879\u2013895","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"8127_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"8127_CR10","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(24):e285\u2013e350","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"8127_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40265-016-0591-2","volume":"76","author":"G Derosa","year":"2016","unstructured":"Derosa G, Maffioli P, Reiner \u017d, Simental-Mendia LE, Sahebkar A (2016) Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs 76(9):947\u2013956","journal-title":"Drugs"},{"issue":"12","key":"8127_CR12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nrd1901","volume":"4","author":"MK Jain","year":"2005","unstructured":"Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4(12):977\u2013987","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"8127_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/MOL.0b013e3283453e41","volume":"22","author":"D-x Bu","year":"2011","unstructured":"Bu D-x, Griffin G, Lichtman AH (2011) Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 22(3):165\u2013170","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"8127_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nri1839","volume":"6","author":"J Greenwood","year":"2006","unstructured":"Greenwood J, Steinman L, Zamvil SS (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6(5):358\u2013370","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"8127_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.atherosclerosis.2010.04.019","volume":"212","author":"Y Ishihara","year":"2010","unstructured":"Ishihara Y, Ohmori K, Mizukawa M, Hasan AU, Noma T, Kohno M (2010) Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis 212(1):131\u2013138","journal-title":"Atherosclerosis"},{"issue":"3","key":"8127_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1567-5688(10)71063-1","volume":"11","author":"AL Catapano","year":"2010","unstructured":"Catapano AL (2010) Pitavastatin\u2013pharmacological profile from early phase studies. Atheroscler Suppl 11(3):3\u20137","journal-title":"Atheroscler Suppl"},{"key":"8127_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1096999","volume":"14","author":"G-L Lin","year":"2023","unstructured":"Lin G-L, Lin H-C, Lin H-L, Keller JJ, Wang L-H (2023) Association between statin use and the risk of gout in patients with hyperlipidemia: a population-based cohort study. Front Pharmacol 14:1096999","journal-title":"Front Pharmacol"},{"issue":"6","key":"8127_CR18","first-page":"1501","volume":"27","author":"K-C Lin","year":"2000","unstructured":"Lin K-C, Lin HY, Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27(6):1501\u20131505","journal-title":"J Rheumatol"},{"issue":"2","key":"8127_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","volume":"23","author":"JA Singh","year":"2011","unstructured":"Singh JA, Reddy SG, Kundukulam J (2011) Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 23(2):192\u2013202","journal-title":"Curr Opin Rheumatol"},{"issue":"13","key":"8127_CR20","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.2174\/0929867330666230207124516","volume":"31","author":"A Akbari","year":"2024","unstructured":"Akbari A, Razmi M, Rafiee M, Watts GF, Sahebkar A (2024) The effect of statin therapy on serum uric acid levels: a systematic review and meta-analysis. Curr Med Chem 31(13):1726\u20131739","journal-title":"Curr Med Chem"},{"issue":"3","key":"8127_CR21","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.4049\/jimmunol.170.3.1524","volume":"170","author":"BP Leung","year":"2003","unstructured":"Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H et al (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170(3):1524\u20131530","journal-title":"J Immunol"},{"issue":"6911","key":"8127_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature01158","volume":"420","author":"S Youssef","year":"2002","unstructured":"Youssef S, St\u00fcve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM et al (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420(6911):78\u201384","journal-title":"Nature"},{"issue":"6","key":"8127_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/sj.bjp.0707250","volume":"151","author":"A Nicholson","year":"2007","unstructured":"Nicholson A, Hajjar D, Zhou X, He W, Gotto Jr, Han J (2007) Anti\u2010adipogenic action of pitavastatin occurs through the coordinate regulation of PPAR\u03b3 and Pref\u20101 expression. Br J Pharmacol 151(6):807\u2013815","journal-title":"Br J Pharmacol"},{"issue":"1","key":"8127_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000112633","volume":"36","author":"N Inami","year":"2008","unstructured":"Inami N, Nomura S, Shouzu A, Omoto S, Kimura Y, Takahashi N et al (2008) Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb 36(1):1\u20138","journal-title":"Pathophysiol Haemost Thromb"},{"key":"8127_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.atherosclerosis.2016.08.009","volume":"253","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Mantzoros CS (2016) Statins in relation to adiponectin: a significant association with clinical implications. Atherosclerosis 253:270\u2013272","journal-title":"Atherosclerosis"},{"issue":"8","key":"8127_CR26","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00125-006-0269-5","volume":"49","author":"M Nakata","year":"2006","unstructured":"Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T (2006) Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 49(8):1881\u20131892","journal-title":"Diabetologia"},{"issue":"1","key":"8127_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.22466","volume":"57","author":"HK Choi","year":"2007","unstructured":"Choi HK, Ford ES, Li C, Curhan G (2007) Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Care Res 57(1):109\u2013115","journal-title":"Arthritis Care Res"},{"key":"8127_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"N Pj","year":"2006","unstructured":"Pj N (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565\u2013581","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08127-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08127-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08127-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:25:23Z","timestamp":1780982723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08127-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8127"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08127-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Tri-Service General Hospital (TSGHIRB No. A202405037). As all data were anonymized and de-identified by the data provider, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}